Aspire Biopharma (ASBP) announced that the Company’s Board of Directors has appointed Kraig Higginson as interim Chief Executive Officer, effective July 24, 2025. Mr. Higginson serves as Chairman of the Board and previously served as CEO of Aspire for four years. Michael C. Howe has resigned as CEO and as a member of the Board. The Board thanks Mr. Howe for his contributions to the Company and plans to initiate a search for a permanent CEO.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASBP:
- Aspire Biopharma Announces Leadership Reshuffle Amid Resignations
- Aspire Biopharma announces ‘positive’ consumer feedback on Buzz Bomb
- Aspire announces last patient dosed in Phase 1 trial of aspirin formulation
- Aspire Biopharma Relocates Executive Office to Florida
- Aspire Biopharma Appoints New CEO Michael C. Howe